Drug Topics

NOVEMBER 3, 2023

By way of natural immunity, vaccination, and behavior change, the majority of the 30,861 documented cases and 54 deaths were confined to 2022, and the epidemic curve portrays a picture of success.

Documentation 98

Documentation Immunization Vaccines 98

pharmaphorum

FEBRUARY 9, 2022

In this article, Ben Hargreaves looks into the promise of cancer vaccines and how this treatment modality may offer advantages over existing immunotherapies in the oncology sector. One area that is gathering increasing levels of interest is the development of cancer vaccines. A broad front.

Vaccines 132

Vaccines Immunization Compounding Pharmaceutical Companies 132

pharmaphorum

SEPTEMBER 22, 2022

Alexandre Le Vert, CEO and co-founder of Osivax, discusses the company’s breakthrough vaccine technology, oligoDOM, and how it’s driving the development of new influenza and SARS-CoV-2 vaccines that attack T-cells, providing a long-lasting effect. The technology.

Vaccines 93

Vaccines Immunization 93

European Pharmaceutical Review

DECEMBER 19, 2023

Many of today’s vaccines are produced in ready-to-inject liquid formulations that must be kept cold to maintain stability. However, this greatly complicates both the worldwide distribution and stockpiling of vaccines and other drugs. A requisite cold chain has been designed and implemented to be uninterrupted from factory to patient.

Vaccines 101

Vaccines Communication Immunization Documentation 101

pharmaphorum

JANUARY 19, 2023

Biotech Vaxxas has announced a partnership agreement with the 2017-established Coalition for Epidemic Preparedness Innovations (CEPI), in order to advance the development of Vaxxas’ needle-free vaccine-patch delivery technology with preclinical testing of an mRNA vaccine patch. The agreement, worth $4.3 The agreement, worth $4.3

Vaccines 105

Vaccines Immunization 105

European Pharmaceutical Review

DECEMBER 2, 2022

Vaccines Europe has unveiled its first pipeline review of its 15 members companies, with 100 vaccine candidates as of July 2022. . The data indicated 46 percent of the vaccine candidates target infections that do not have an available vaccine. Improve access and convenience to immunisation for adults.

Vaccines 95

Vaccines Immunization 95

pharmaphorum

DECEMBER 6, 2021

A trial of booster vaccinations to protect against COVID-19 has shown that the jab significantly strengthens the body’s T-cell immunity against the disease. Several COVID-19 vaccines were used in the trial – all were administered via intramuscular injection into the upper arm.

Immunization 52

Immunization Vaccines Hospitals 52

Pharmaceutical Technology

FEBRUARY 3, 2023

Only a few weeks into the new year, the prospect of getting a successful advanced HIV vaccine shrank after the discontinuation of yet another late-stage trial. On January 18, Janssen, a Johnson & Johnson (J&J) subsidiary, stated that its vaccine was not effective in preventing HIV infections.

Vaccines 117

Vaccines Immunization 117

pharmaphorum

DECEMBER 4, 2020

Valneva has said it plans to accelerate research into its Lyme disease vaccine candidate VLA15, bringing forward a trial including children into the first quarter of 2021. Pfizer will pay up to $45 million in development related milestone payments and up to $143 million if the vaccine hits early sales targets.

Vaccines 119

Vaccines Immunization 119

pharmaphorum

JUNE 21, 2021

It would be easy to forget that back in 2019, BioNTech was an early-stage biotech firmly focused on cancer vaccines, before being catapulted onto the world-stage with its COVID-19 shot. Among the 25-strong group given the vaccine on its own, there was one patient who had a complete remission of tumours that had spread from the original site.

Vaccines 145

Vaccines Immunization 145

European Pharmaceutical Review

NOVEMBER 18, 2022

The World Health Organization (WHO)’s Global Vaccine Market Report 2022 , the first report to examine the impact of COVID-19 on the global vaccine market, shows that inequitable distribution is not unique to COVID-19 vaccines, with poorer countries consistently fighting to access vaccines in demand by wealthier countries.

Vaccines 84

Vaccines Immunization Documentation 84

Hospital Pharmacy Europe

JANUARY 25, 2023

The Joint Committee on Vaccination and Immunisation (JCVI) has advised offering Covid booster vaccinations in spring and autumn 2023 for patients deemed to be at high risk. That is why we have advised planning for further booster vaccines for persons at higher risk of serious illness through an autumn booster programme later this year.

Vaccines 98

Vaccines Immunization Hospitals 98

European Pharmaceutical Review

OCTOBER 21, 2022

GSK announced Shingrix (Zoster Vaccine Recombinant, Adjuvanted), the first approved shingles vaccine to combine a non-live antigen with a GSK-made adjuvant, can prevent shingles (herpes zoster) for at least decade. An interim analysis conducted over more than four years of long-term follow-up (LTFU) showed vaccine efficacy was 81.6

Vaccines 88

Vaccines Immunization 88

Pharmacy Times

JUNE 23, 2022

Vaxneuvance was approved for an expanded indication by the FDA on June 22, 2022, for active immunization in children 6 weeks of age and older.

Immunization 123

Immunization Vaccines FDA 123

European Pharmaceutical Review

AUGUST 2, 2022

GSK has signed a framework contract with the European Commission’s (EC) Health Emergency Preparedness and Response Authority (HERA) for the reservation of future production and supply of 85 million doses of its pandemic influenza vaccine Adjupanrix [pandemic influenza vaccine (split virion, inactivated, adjuvanted)].

Vaccines 82

Vaccines Immunization 82

pharmaphorum

AUGUST 12, 2021

The UK government has started ordering COVID-19 vaccines for a 2022 booster campaign, including a 32 million-dose order for the Pfizer/BioNTech shot, even before third doses for 2021 have been given the go-ahead. The Johnson & Johnson vaccine is also supplied on a no-profit basis. Pricing slammed.

Vaccines 111

Vaccines Immunization 111

European Pharmaceutical Review

AUGUST 22, 2022

THE GLOBAL outbreak of the COVID-19 pandemic triggered an urgent need to protect people’s lives and livelihoods and the healthcare community recognised quite early that vaccines were the best solution to this crisis. Novel biotechnology platforms for vaccine development.

Vaccines 89

Vaccines Immunization 89

Digital Pharmacist

OCTOBER 26, 2022

On October 7 th , 2022 the U.S. Children aged 2 months of age or younger are not eligible for the Tdap vaccine. The lack of solid data around the effectiveness and safety of the Tdap vaccine on the newborn itself was what led to further research. formulation of the vaccine, except that the non-U.S. Background of Boostrix.

Vaccines 98

Vaccines FDA Hospitals Immunization 98

DiversifyRx

OCTOBER 5, 2022

Here are the 10 most exciting companies I saw at the 2022 NCPA annual convention. NCPA held its 2022 annual convention in Kansas City. Many people are curious to know if their antibody levels are high or low and how they change after a vaccine booster or a sickness. NCPA Annual Convention 2022 Wrap Up.

Independent Pharmacies 98

Independent Pharmacies Vaccines Compounding Immunization 98

pharmaphorum

AUGUST 16, 2022

Following the success of LNP-mRNA vaccines, we have seen an influx of novel types of lipids based nanocarriers over the last 12 months, progress has been made to minimize immuno-toxicity challenges – from maximizing therapeutic window to fine-tuning the immune response. . Download the full event guide to find out more.

Immunization 52

Immunization Vaccines 52

Pharmaceutical Technology

JUNE 8, 2023

Gritstone bio has reported interim results from an ongoing Phase 1 study evaluating the company’s self-amplifying mRNA (samRNA) vaccine as a boost against Covid-19 (CORAL-BOOST). These results were first reported by Gritstone in October 2022. According to GlobalData , there are over 800 Covid-19 vaccines in the pipeline, 42.6%

Vaccines 52

Vaccines Immunization Communication 52

Hospital Pharmacy Europe

FEBRUARY 15, 2023

COVID-19 vaccines had an enormous impact on hospitalisations and mortality due to infection with the virus yet is has become recognised that induced antibody levels reduce over time. Vaccine effectiveness against COVID-19 outcomes A total of 68 studies were included in the final analysis. Citation Wu N et al.

Vaccines 52

Vaccines Immunization Hospitals 52

European Pharmaceutical Review

AUGUST 26, 2022

Moderna has filed patent infringement lawsuits alleging that Pfizer and BioNTech’s COVID-19 vaccine Comirnaty ® infringes patents Moderna filed between 2010 and 2016 covering its foundational messenger RNA (mRNA) technology. Pfizer and BioNTech copied this technology, without Moderna’s permission, to make Comirnaty,” said Moderna.

Vaccines 89

Vaccines Immunization 89

pharmaphorum

DECEMBER 2, 2021

Health and Social Care Secretary, Sajid Javid, announced the move as researchers race to uncover the effect of existing vaccines on the Omicron variant, which was first identified by scientists in South Africa. Up to 60 million doses of Moderna’s vaccine, which may include authorised booster doses, were given the green light.

Vaccines 52

Vaccines Immunization 52

Hospital Pharmacy Europe

NOVEMBER 24, 2022

A fentanyl vaccine induced significant antibody levels and reduced brain levels of the drug and could be of value in opiate use disorder. The principle is simple: a conjugate vaccine is designed to elicit an immune response to the abused opioid (e.g., Fentanyl vaccine effectiveness. Pharmaceutics 2022.

Vaccines 59

Vaccines Immunization Hospitals 59

European Pharmaceutical Review

JANUARY 23, 2023

We are extremely pleased that our cancer vaccine candidate EVX-01 has received the FDA fast track designation, as it enables a potentially faster approval of the vaccine,” stated Per Norlén, CEO at Denmark-based Evaxion. The FTD is for EVX-01, in combination with Keytruda ® for patients with metastatic melanoma (MM). ”We Moderna, Inc.

Immunization 122

Immunization Vaccines FDA 122

pharmaphorum

AUGUST 26, 2022

The rivalry between Moderna and Pfizer/BioNTech in commercialising their COVID-19 vaccines has now spilled over into the courts, in the form of a patent infringement lawsuit. ” There’s no world yet on whether a counter-suit may be in the offing. .” Lawsuits sprouting like mushrooms.

Vaccines 59

Vaccines Immunization 59

Pharmaceutical Technology

AUGUST 26, 2022

Amid a shortage of monkeypox vaccine doses, the WHO and FDA have declared public health emergencies, and the FDA has granted its first Emergency Use Authorization (EUA) to a monkeypox vaccine and opened the door for more. On the same day, the FDA granted a EUA to Bavarian Nordic’s (Copenhagen, Denmark) Jynneos vaccine.

Vaccines 52

Vaccines FDA Immunization 52

pharmaphorum

SEPTEMBER 15, 2020

billion) order for up to 190 million doses of a coronavirus vaccine in development at French company Valneva. The new deal firms up an earlier agreement in principle with the UK in July that covered up to 100 million doses of VLA2001 , a purified inactivated SARS-CoV-2 vaccine that is expected to require a two-dose vaccination regimen.

Vaccines 64

Vaccines Immunization 64

Hospital Pharmacy Europe

NOVEMBER 7, 2022

The mRNA-1273 vaccine has been shown to generate an antibody response in children from 6 months which is non-inferior to that of young adults. However, whether the vaccine remains safe and able to elicit a satisfactory antibody response in children from 6 months of age is uncertain and was the purpose of the present study.

Vaccines 52

Vaccines Immunization Hospitals 52

pharmaphorum

APRIL 6, 2021

People in the UK will start receiving doses of Moderna’s COVID-19 vaccine in around two weeks’ time, according to vaccines minister Nadhim Zahawi. Moderna’s vaccine is around 94% effective at preventing the disease, in line with the results seen from the Pfizer/BioNTech shot, which is also based around mRNA technology.

Vaccines 80

Vaccines Immunization 80

pharmaphorum

DECEMBER 15, 2022

Stefan Woxström is the new senior vice president for Europe and Canada at AstraZeneca, moving over from the company’s Japanese division to take over from Iskra Reic , who will now serve as EVP of vaccines and immune therapies. Prior to 2022, she did sales and marketing at Pfizer, Allergan, DuPont Pharma, and Johnson & Johnson.

Immunization 52

Immunization Vaccines 52

European Pharmaceutical Review

MAY 7, 2024

Injectable vaccines activate the immune system to help to prevent infectious conditions such as influenza. Additionally, GSK BOOSTRIX’s (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine , Adsorbed; Tdap) was approved for infants under two months old, in Oct 2022.

Vaccines 70

Vaccines Compounding Immunization FDA 70

pharmaphorum

MARCH 17, 2022

Alnylam claims it is owed a slice of the massive revenues booked by Pfizer and Moderna for their mRNA-based COVID-19 vaccines, because they are both infringing patents its holds on a delivery technology. Pfizer made $36 billion in sales from Comirnaty last year, and is expecting to shift another $32 billion-worth in 2022.

Vaccines 52

Vaccines Immunization 52

pharmaphorum

JANUARY 13, 2022

Preliminary data from an ongoing trial of AstraZeneca’s COVID-19 vaccine Vaxzevria has shown that a booster dose stimulates an increase in antibodies against Omicron, as well as other variants of the virus, including Alpha, Beta, Delta, and Gamma. billion doses administered. That’s only a little shy of the 2.6

Vaccines 96

Vaccines Immunization 96

Pharmaceutical Technology

OCTOBER 28, 2022

On 24 October, American vaccine developer Vaxcyte shared positive topline data from a Phase I/II study of its multivalent conjugate pneumococcal vaccine VAX-24 , bringing the 24-valent pneumococcal jab one step closer to market. What’s more, VAX-24 achieved a higher immune response to 16 of the 20 serotypes it shares with Prevnar 20.

Vaccines 64

Vaccines FDA Immunization 64

Digital Pharmacist

AUGUST 21, 2023

The most effective preventive measure against the flu is getting an annual flu vaccine. Getting Vaccinated for the Flu The CDC says ideally, everyone who is eligible for a flu vaccine should be vaccinated by the end of October – the ideal time to get vaccinated being September or October.

Vaccines 98

Vaccines Communication Immunization 98